Spero Therapeutics to Present at Upcoming September Investor Conferences
CAMBRIDGE, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the H.C. Wainwright 26th Annual Global Investment Conference to be held in New York, NY, September 9th – 11th, 2024. He will also participate in a fireside chat and be available for one-on-one meetings at Cantor’s Global Healthcare Conference in New York, NY, September 17th – 19th, 2024. Details are as follows:
| H.C. Wainwright 26th Annual Global Investment Conference | |
| Presentation Date: | September 10, 2024 |
| Time: | 4:00 - 4:30 PM ET |
| Webcast link: | |
| Cantor’s Global Healthcare Conference | |
| Analyst Fireside Chat: | September 17, 2024 |
| Time: | 1:20 - 1:50 PM ET |
| Webcast link: | |
The webcasts may also be accessed through Spero’s website on the “Events and Presentations” page (). A replay will be available on the website following the conclusion of the event.
About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and MDR bacterial infections.
For more information, visit .
Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
Media Inquiries:
